Companies / Anavex Life Sciences Corp.

Anavex Life Sciences Corp.

Nasdaq: AVXLCIK 1314052NEW YORK, NY

Financials

Revenue—
Net income$-46.38M
Total debt$345
Cash$131.75M
Diluted EPS$-0.54
Shares outstanding92.7M

Ownership

92.7M shares outstanding · as of Feb 9, 2026
41.7%Institutions
Ownership
Institutions41.75%38,687,655
Public float58.25%53,984,103

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
Boenisch SandraPFO & Treasurer
——
Kellmeyer TerrieCEOInterim CEO
——
Missling Christopher UCEOPresident and CEO · Director
——
Paeger AxelDirector
——

Institutional holders 189

View all →
HolderValue% of shares
BlackRock, Inc.$20.86M8.69%
Vanguard Group Inc$17.90M5.43%
Two Sigma Investments, LP$9.97M3.50%
Geode Capital Management, LLC$6.72M2.36%
State Street Corporation$4.98M2.07%
Nwam LLC$4.37M0.94%
Two Sigma Advisers, LP$4.31M1.31%
Summit Financial, LLC$3.22M0.97%
The Goldman Sachs Group, Inc.$3.11M0.94%
Jane Street Group, LLC$2.74M0.83%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jan 6, 2026Boenisch Sandra
Executive
GrantStock Option (Right to Buy)—+13K
12,500
0.01% of shares
low
Jan 6, 2026Missling Christopher U
CEO
GrantStock Option (Right to Buy)—+125K
125,000
0.13% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A—0—

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
AVXL——032797300—